CGEM NASDAQ
Cullinan Therapeutics, Inc.
1W: +0.1%
1M: -0.7%
3M: -13.8%
YTD: +46.6%
1Y: +91.2%
3Y: +70.0%
5Y: -31.0%
$14.84
+0.30 (+2.06%)
Pre-Market: $14.90 (+0.06, +0.40%)
Weekly Expected Move ±9.6%
$12
$13
$14
$16
$17
Credit Risk of going bust: lower than 76% of companies Debt: 0.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Cullinan Therapeutics, Inc. would be worth roughly what it owes.
Total debt $2.1M against a stock market value of $912.0M.
Distance to default 8.84 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $702K (short-term plus half of long-term), stock volatility 78.2%; Altman Z'' 3.42. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Cullinan Therapeutics, Inc. would be worth roughly what it owes.
Total debt $2.1M against a stock market value of $912.0M.
Distance to default 8.84 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $702K (short-term plus half of long-term), stock volatility 78.2%; Altman Z'' 3.42. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
9 relationships9
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2022-05-12
Earliest Filing
2025-06-04
Latest Filing
partner: 4
investor: 2
acquirer: 2
target: 1
Counterparties (Filed by CGEM)
9 relationshipsCompanies named in CGEM's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Chongqing Genrix Biopharmaceutical Co., Ltd. | — | partner | Genrix granted Cullinan an exclusive license to develop and commercialize velinotamig in all fields of use outside of gr | 2025-06-04 | View |
| Harbour BioMed US Inc. | — | partner | Entered into a License and Collaboration Agreement granting Cullinan an exclusive license for HBM7008 in the U.S. | 2023-02-14 | View |
| Avalon Ventures | AWX | investor | Counterparty in Stock Purchase and Transfer Agreement for Series A Preferred Stock of MICA | 2022-10-25 | View |
| Bregua Corporation | — | investor | Counterparty in Stock Purchase and Transfer Agreement for Series A Preferred Stock of MICA | 2022-10-25 | View |
| Cullinan MICA Corp. | — | target | Partially owned subsidiary whose preferred stock was purchased by the registrant | 2022-10-25 | View |
| Taiho Pharmaceutical Co., Ltd. | — | acquirer | Acquired all equity interests in Cullinan Pearl Corp. from Cullinan Oncology, Inc. | 2022-06-27 | View |
| Taiho Oncology, Inc. | — | partner | Entered into a Co-Development Agreement with Cullinan Oncology, Inc. to co-develop the Lead Program. | 2022-06-27 | View |
| Taiho Pharmaceutical Co., Ltd. | — | acquirer | Acquired Cullinan Oncology's subsidiary Cullinan Pearl Corp. for $275 million upfront plus potential milestones. | 2022-05-12 | View |
| Taiho Oncology, Inc. | — | partner | Partnered with Cullinan Oncology to co-develop and co-promote the CLN-081/TAS6417 lead program in the U.S. | 2022-05-12 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-02 | Regulation FD; Other Events; Exhibits | View | |
| 2026-09-24 | Regulation FD; Other Events; Exhibits | View | |
| 2026-09-14 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-13 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-06-16 | Shareholder Vote | View | |
| 2026-06-10 | Regulation FD; Other Events; Exhibits | View | |
| 2026-06-08 | Regulation FD; Other Events; Exhibits | View | |
| 2026-05-18 | Regulation FD; Other Events; Exhibits | View | |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-03-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-08 | Results of Operations and Financial Condition; Regulation FD Disclosure; Other Events; Financial Sta | View | |
| 2025-12-08 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-21 | Termination of Material Definitive Agreement | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-03 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-09-04 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2025-06-12 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-06-04 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR